SCIGNALS

SCIGNALS operates at the intersection of neurotechnology, biomedical instrumentation, and digital health. Its stated approach combines neuroscience, electronics, hardware, software, and signal processing, with applications ranging from research recording and analysis to neuromonitoring and neurorehabilitation. Signalino addresses biomedical signal acquisition and analysis, while Scignabot applies brain-computer-interface control to a robotic rehabilitation system; MemBoost represents a cognitive-enhancement research direction. Its stated collaborations with Fundación Instituto San José and the Human Brain Project community indicate links to clinical and research environments, but do not by themselves establish market share or commercial traction. The 2019 SME Instrument Phase 1 funding of €50,000 suggests support for an early-stage development effort; no later financing or valuation is provided to clarify its current competitive scale.

The clearest dated financial milestone is a €50,000 SME Instrument Phase 1 award in 2019, associated with Horizon 2020. That support is approximately $56,000, subject to exchange-rate variation, and indicates an early development-stage funding event rather than evidence of a later venture round. The company’s technology portfolio includes Signalino for biomedical signal recording and analysis, Scignabot for BCI-controlled robotic neurorehabilitation, and MemBoost, a memory- and sleep-related cognitive enhancement project. Hiring news is unavailable, and there is no employee-growth series, subsequent funding event, or product-launch timeline to identify a later inflection point. Accordingly, the evidence supports a trajectory of research-driven product development since at least the 2019 funding milestone, while the pace of growth and current operating scale remain unclear.